-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
BioNexus Gene Lab Corp quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q2 2022 to Q2 2023.
- BioNexus Gene Lab Corp Deferred Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $16K, a 886% increase year-over-year.
- BioNexus Gene Lab Corp annual Deferred Income Tax Expense (Benefit) for 2022 was -$3.9K, a 85.4% increase from 2021.
- BioNexus Gene Lab Corp annual Deferred Income Tax Expense (Benefit) for 2021 was -$26.7K, a 2260% decline from 2020.
- BioNexus Gene Lab Corp annual Deferred Income Tax Expense (Benefit) for 2020 was $1.24K, a 72.3% decline from 2019.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)